Key facts
- It has raised $100.9M; the latest was Early Stage VC ($97.2M) in Dec 2025.
- Notable investors include European Innovation Council, CDP Venture Capital (Rome), Sofinnova Partners, Panakes Partners, European Innovation Council (Belgium) — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for NanoPhoria Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for NanoPhoria Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NanoPhoria Bioscience
Developer of a non-viral drug delivery platform designed to offer inorganic nanoparticle-based treatment. The company's platform allows selective targeting at the organ and cellular level to provide treatment for heart failure with reduced ejection fraction (HFrEF), enabling medical practitioners to save the lives of patients with cardiac diseases.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Founded
- 2022
- Employees
- 4
- Website
- nanophoria.com/
- Ownership
- Privately Held (backing)
NanoPhoria Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NanoPhoria Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NanoPhoria Bioscience in its N-PORT filings yet. We sweep new filings monthly.